A seldom-discussed global health threat may soon have a U.S. Food and Drug Administration (FDA)- approved vaccine available.
Valneva SE and LimmaTech Biologics AG today announced that the U.S. FDA has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate.
Shigella Vaccine Candidate Awarded U.S. FDA Fast Track Designation
Disparities Observed in Mortality During COVID-19 Pandemic
18.3 percent fewer deaths would have occurred had the rate of excess mortality seen in Whites been the same in total population
Risk for Type 2 Diabetes Increased for Children After SARS-CoV-2 Infection
Risk increased in the six months after infection; elevated risk also seen in subpopulation with overweight, obesity and hospitalized patients
Risk for Most Cardiovascular Events Reduced After COVID-19 Vaccination
Increased risk for myocarditis, pericarditis seen one to two weeks after COVID-19 mRNA vaccination
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 16, 2024 (HealthDay News) — Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows.About …